中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

96 records (took 0.03 seconds)

    Methods of propagating monkey adenoviral vectors
    83.
    发明授权
    Methods of propagating monkey adenoviral vectors 有权
    繁殖猴腺病毒载体的方法

    公开(公告)号：US09586998B2

    公开(公告)日：2017-03-07

    申请号：US14817910

    申请日：2015-08-04

    Applicant: GenVec, Inc.

    Inventor： Jason Gall ,  Douglas Brough ,  Christoph Kahl ,  Duncan McVey

    IPC: C07K14/005 ,  C12N15/86 ,  C12N7/00

    CPC classification number: C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/10322 ,  C12N2710/10332 ,  C12N2710/10343 ,  C12N2710/10352

    Abstract: The invention provides methods for propagating a monkey adenovirus in a cell, including a human cell, comprising one or more gene products isolated from a human adenovirus. Also provided are methods for propagating wherein the monkey adenovirus comprises a nucleic acid sequence encoding a human adenovirus gene product. The invention further provides a monkey adenovirus, including a replication-deficient monkey adenovirus, obtained by such propagation methods.

    Abstract translation: 本发明提供了在细胞中繁殖猴腺病毒的方法，包括人细胞，其包含从人腺病毒分离的一种或多种基因产物。 还提供了用于繁殖的方法，其中猴腺病毒包含编码人腺病毒基因产物的核酸序列。 本发明还提供了通过这种繁殖方法获得的猴腺病毒，其包括复制缺陷型猴腺病毒。

    MALARIA ANTIGENS AND METHODS OF USE
    85.
    发明申请
    MALARIA ANTIGENS AND METHODS OF USE 有权
    MALARIA抗原和使用方法

    公开(公告)号：US20150297699A1

    公开(公告)日：2015-10-22

    申请号：US14441988

    申请日：2013-11-12

    Applicant: GENVEC, INC.

    Inventor： Ping Chen ,  Duncan McVey ,  Douglas Brough ,  Joseph Bruder

    IPC: A61K39/015

    CPC classification number: A61K39/015 ,  A61K2039/5256 ,  A61K2039/53 ,  Y02A50/412

    Abstract: The invention is directed to a composition comprising one or more polypeptides or one or more nucleic acid sequences that can induce a protective immune response against Plasmodium species that infect humans. The invention also is directed to a method of using such compositions to induce a protective immune response against a Plasmodium parasite in a mammal.

    Abstract translation: 本发明涉及包含一种或多种多肽或一种或多种可诱导针对感染人的疟原虫物种的保护性免疫应答的核酸序列的组合物。 本发明还涉及使用这样的组合物来诱导针对哺乳动物的疟原虫寄生虫的保护性免疫应答的方法。

    Materials and methods for treating disorders of the ear
    87.
    发明申请
    Materials and methods for treating disorders of the ear 审中-公开
    用于治疗耳朵疾病的材料和方法

    公开(公告)号：US20040166091A1

    公开(公告)日：2004-08-26

    申请号：US10373249

    申请日：2003-02-24

    Applicant: GenVec, Inc.

    Inventor： Douglas E. Brough

    IPC: A61K048/00 ,  C12N015/861

    CPC classification number: A61K38/17 ,  A61K38/00 ,  A61K48/005 ,  A61P27/00 ,  C07K14/4702 ,  C12N7/00 ,  C12N15/86 ,  C12N2501/60 ,  C12N2710/10343

    Abstract: The invention is directed to a method of changing the sensory perception of an animal. The method comprises administering an expression vector comprising a nucleic acid sequence encoding an atonal-associated factor, which is expressed to produce the atonal-associated factor resulting in generation of hair cells that allow perception of stimuli in the inner ear. Also provided is a method of generating a hair cell in differentiated sensory epithelia in vivo. The method comprises contacting differentiated sensory epithelial cells with an adenoviral vector (a) deficient in one or more replication-essential gene functions of the E1 region and E4 region, (b) comprising a spacer in the E4 region, and (c) comprising a nucleic acid sequence encoding an atonal-associated factor. The nucleic acid sequence is expressed to produce the atonal-associated factor such that a hair cell is generated. An adenoviral vector encoding an atonal-associated factor also is provided.

    Abstract translation: 本发明涉及一种改变动物的感觉知觉的方法。 所述方法包括施用包含编码无关联因子的核酸序列的表达载体，所述核酸序列被表达以产生导致产生能够感知内耳中的刺激的毛细胞的无关性因子。 还提供了一种在体内在分化感觉上皮细胞中产生毛细胞的方法。 该方法包括使分化的感觉上皮细胞与E1区和E4区的一个或多个复制必需基因功能缺陷的腺病毒载体（a）接触，（b）在E4区中包含间隔基，和（c）包含 编码无关联因子的核酸序列。 表达核酸序列以产生无创因子，从而产生毛细胞。 还提供了编码无关联因子的腺病毒载体。

    Replication deficient adenoviral TNF vector
    88.
    发明申请
    Replication deficient adenoviral TNF vector 审中-公开

    公开(公告)号：US20030175245A1

    公开(公告)日：2003-09-18

    申请号：US10424638

    申请日：2003-04-25

    Applicant: GenVec, Inc.

    Inventor： Douglas E. Brough ,  C. Richter King ,  Imre Kovesdi ,  Jasper J. Schaible

    IPC: A61K048/00 ,  C12N007/00 ,  C12N015/861

    CPC classification number: C12N15/86 ,  A61K38/191 ,  A61K48/00 ,  C12N2710/10343 ,  C12N2810/40

    Abstract: An adenoviral vector comprising (a) an adenoviral genome deficient in the E4 region of the adenoviral genome, (b) a nucleic acid sequence coding for TNF, and (c) a radiation inducible promoter operably linked to the nucleic acid sequence coding for TNF. This invention also provides an adenoviral vector comprising (a) an adenoviral genome deficient in the E4 region of the adenoviral genome, (b) a nucleic acid sequence coding for TNF, and (c) a spacer element of at least 15 base pairs in the E4 region of the adenoviral genome. A method of producing an adenoviral vector and a method of treating a tumor or cancer in a host comprising administering an anti-cancer or anti-tumor effective amount of the adenoviral vector of the present invention also is provided.

    Method and composition for targeting an adenoviral vector
    89.
    发明申请
    Method and composition for targeting an adenoviral vector 审中-公开
    用于靶向腺病毒载体的方法和组合物

    公开(公告)号：US20030099619A1

    公开(公告)日：2003-05-29

    申请号：US10304160

    申请日：2002-11-25

    Applicant: GenVec, Inc.

    Inventor： Thomas J. Wickham ,  Imre Kovesdi ,  Petrus W. Roelvink ,  David Einfeld ,  Douglas E. Brough ,  Alena Lizonova

    IPC: A61K048/00 ,  C12Q001/70 ,  C12N015/861 ,  C07K014/705 ,  C07K014/075

    CPC classification number: C12N15/86 ,  A61K48/00 ,  C12N2710/10343 ,  C12N2710/10345 ,  C12N2810/40 ,  C12N2810/405 ,  C12N2810/60 ,  C12N2810/80 ,  C12N2830/008

    Abstract: The invention provides adenoviral coat proteins comprising various non-native ligands. Further, the present invention provides an adenoviral vector that elicits less reticulo-endothelial system (RES) clearance in a host animal than a corresponding wild-type adenovirus. Also provided by the invention is a system comprising a cell having a non-native cell-surface receptor and a virus having a non-native ligand, wherein the non-native ligand of the virus binds the non-native cell-surface receptor of the cell. Using this system, a virus can be propagated. Further provided by the invention is a method of controlled gene expression utilizing selectively replication competence, a method of assaying for gene function, a method of isolating a nucleic acid, and a method of identifying functionally related coding sequences. Additionally, the invention provides a cell-surface receptor, which facilitates internalization.

    Abstract translation: 本发明提供了包含各种非天然配体的腺病毒外壳蛋白。 此外，本发明提供了一种腺病毒载体，其在宿主动物中比相应的野生型腺病毒引起较少的网状内皮系统（RES）清除。 本发明还提供了一种包含具有非天然细胞表面受体的细胞和具有非天然配体的病毒的系统的系统，其中所述病毒的非天然配体结合所述非天然细胞表面受体的非天然细胞表面受体 细胞。 使用该系统可以传播病毒。 本发明进一步提供了利用选择性复制能力的受控基因表达的方法，基因功能测定方法，分离核酸的方法和识别功能相关编码序列的方法。 另外，本发明提供了促进内化的细胞表面受体。

    Therapeutic regimen for treating cancer
    90.
    发明申请
    Therapeutic regimen for treating cancer 有权
    治疗癌症的治疗方案

    公开(公告)号：US20030086904A1

    公开(公告)日：2003-05-08

    申请号：US10151633

    申请日：2002-05-17

    Applicant: GenVec, Inc.

    Inventor： Henrik S. Rasmussen ,  Karen W. Chu

    IPC: A61K048/00 ,  C12N007/00 ,  C12N015/861

    CPC classification number: A61K35/761 ,  A61K38/191 ,  C12N2710/10332 ,  C12N2710/10341 ,  A61K2300/00

    Abstract: The invention provides a method for treating cancer in a human comprising administering to the human a dose of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) an adenoviral vector comprising a nucleic acid sequence encoding TNF-null operably linked to a promoter, wherein the dose comprises about 1null107 to about 4null1012 particle units (pu) of replication-deficient adenoviral vector, at least once in a therapeutic period comprising up to 10 weeks, whereby the cancer in human is treated. The invention further provides a method of treating a human for multiple tumors, wherein the method comprises contacting a first tumor with a dose of the pharmaceutical composition at least once in a therapeutic period comprising up to about 10 weeks, whereby the human is treated for the first tumor and one or more additional tumors.

    Abstract translation: 本发明提供了一种治疗人类癌症的方法，包括向人施用剂量的药物组合物，其包含（i）药学上可接受的载体和（ii）腺病毒载体，其包含编码与α-α可操作地连接的TNF-α的核酸序列 启动子，其中所述剂量包含约1×10 7至约4×10 12个复制缺陷型腺病毒载体的颗粒单位（pu），在至多10周的治疗期内至少一次，由此治疗人类的癌症。 本发明进一步提供了治疗多种肿瘤的方法，其中所述方法包括使第一肿瘤与一定剂量的药物组合物在至多约10周的治疗期内至少接触一次，由此将该人治疗为 第一肿瘤和一个或多个另外的肿瘤。

Patent Agency Ranking